title: Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2.
abstract: The chimeric gene, AML1/ETO (MTG8), generated in t(8;21) acute myeloid leukemia enhances the expression of Bcl-2. To evaluate whether this enhancement is the primary role of AML1/ETO in leukemogenesis, effects of over-expression of Bcl-2 in the murine myeloid precursor cell line, 32Dcl3, were examined. When 32Dcl3 cells expressing exogenous Bcl-2 were induced to differentiate, the onset of morphological differentiation was delayed. However, even the cells expressing very high levels of exogenous Bcl-2 eventually underwent differentiation without a significant decrease in the synthesis of Bcl-2. On the contrary, 32Dcl3 cells stably expressing AML1/ETO were completely resistant to differentiation and continued to grow in the presence of G-CSF. These results are consistent with the interpretation that stimulation of Bcl-2 expression is not the primary target of AML1/ETO.
authors.affiliation: Department of Viral Oncology, Institute for Virus Research, Kyoto University, Shogoin, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Kohzaki
authors.forename: K
authors.initials: K
authors.lastname: Ito
authors.forename: G
authors.initials: G
authors.lastname: Huang
authors.forename: H J
authors.initials: HJ
authors.lastname: Wee
authors.forename: Y
authors.initials: Y
authors.lastname: Murakami
authors.forename: Y
authors.initials: Y
authors.lastname: Ito
mesh_terms: D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics / Q000648:ultrastructure; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics / Q000648:ultrastructure; D050676:Core Binding Factor Alpha 2 Subunit; D015973:Gene Expression Regulation, Leukemic; D019254:Genes, bcl-2; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D006098:Granulocytes / Q000166:cytology*; D018922:HL-60 Cells / Q000378:metabolism / Q000473:pathology; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007377:Interleukin-3 / Q000494:pharmacology; D020014:K562 Cells / Q000378:metabolism / Q000473:pathology; D007951:Leukemia, Myeloid / Q000473:pathology; D051379:Mice; D014411:Neoplastic Stem Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D015514:Oncogene Proteins, Fusion; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000502:physiology*; D000075142:RUNX1 Translocation Partner 1 Protein; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000502:physiology; D011994:Recombinant Proteins / Q000494:pharmacology; D014157:Transcription Factors / Q000235:genetics / Q000502:physiology*; D014162:Transfection; D014178:Translocation, Genetic; D014407:Tumor Cells, Cultured; D020298:U937 Cells / Q000378:metabolism / Q000473:pathology
chemical_list: C107844:AML1-ETO fusion protein, human; D050676:Core Binding Factor Alpha 2 Subunit; D007377:Interleukin-3; D015514:Oncogene Proteins, Fusion; D019253:Proto-Oncogene Proteins c-bcl-2; D000075142:RUNX1 Translocation Partner 1 Protein; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D014157:Transcription Factors; D016179:Granulocyte Colony-Stimulating Factor